Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($) |
3 Months Ended | 6 Months Ended | |||||
---|---|---|---|---|---|---|---|
Feb. 01, 2022 |
Jan. 21, 2020 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jan. 31, 2020 |
|
Commercial Services And Loan Agreements [Line Items] | |||||||
Selling, general and administrative | $ 5,134,902 | $ 3,733,450 | $ 9,432,407 | $ 6,872,986 | |||
Eversana Agreement [Member] | |||||||
Commercial Services And Loan Agreements [Line Items] | |||||||
Unreimbursed commercialization cost | 79,800,000 | $ 79,800,000 | |||||
Agreement expiration date | Dec. 31, 2026 | ||||||
Agreement term | On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms (the “Eversana Amendment”). | ||||||
Selling, general and administrative | $ 3,200,000 | $ 2,200,000 | $ 5,800,000 | $ 3,600,000 | |||
Eversana Agreement [Member] | Revolving Credit Facility [Member] | |||||||
Commercial Services And Loan Agreements [Line Items] | |||||||
Line of credit | $ 5,000,000 | ||||||
Line of credit facility, Interest rate | 10.00% | ||||||
Borrowings | $ 5,000,000 | ||||||
Eversana Agreement [Member] | Gimoti [Member] | Minimum [Member] | |||||||
Commercial Services And Loan Agreements [Line Items] | |||||||
Percentage of Product Profits | 80.00% |